BCM
KYNB

Bluefin Capital Management’s Kyntra Bio KYNB Stock Holding History

Bluefin Capital Management’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-604
Closed -$4K – 508
2019
Q4 		$4K Buy
+604
New +$617K ﹤0.01% 556

Other funds holding KYNB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Bluefin Capital Management's KYNB Position: Q1 2020 in Review

Bluefin Capital Management sold out of Kyntra Bio (KYNB) in Q1 2020, closing a stake of 2,864 shares — an estimated $3.07M sold.

Bluefin Capital Management first reported a position in KYNB in Q4 2019 and held it in 1 quarter. The position peaked at $3.07M in Q4 2019. 187 funds tracked by Wall St. Rank hold KYNB as of Q1 2020.

  • Bluefin Capital Management reported no remaining Kyntra Bio position as of Q1 2020 after selling out during the quarter.
  • Bluefin Capital Management sold 2,864 Kyntra Bio shares in Q1 2020, an estimated $3.07M.
  • Bluefin Capital Management first reported a position in Kyntra Bio in Q4 2019 and held it in 1 quarter.
  • Bluefin Capital Management's Kyntra Bio position peaked at $3.07M in Q4 2019.
  • 187 funds tracked by Wall St. Rank held Kyntra Bio as of Q1 2020.

Based on Bluefin Capital Management's 13F filing for Q1 2020, filed 15 May 2020.